Eli Lilly and Company (LLY) is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc.
On May 13, 2022, LLY announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection. LLY’s President Mike Mason said, “We are thrilled to introduce Mounjaro, which represents the first new class of type 2 diabetes medication introduced in almost a decade and embodies our mission to bring innovative new therapies to the diabetes community.”
